Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/11/2003US20030229904 Comprises polypeptide for diagnosis, treatment and prevention of tumors
12/11/2003US20030229226 Cathepsin cysteine protease inhibitors
12/11/2003US20030229225 Novel phosphonic acid based prodrugs of PMEA and its analogues
12/11/2003US20030229199 Modulator comprising cyclic peptide for use in treatment of cancer, gastrointestinal, inflammatory and nervous system disordrers
12/11/2003US20030229140 Plant extracts; chlorogenic acid
12/11/2003US20030229136 Anticancer agents; antiproliferative agents
12/11/2003US20030229135 Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxycarbonyl]-5-oxazolidine carboxylic acids
12/11/2003US20030229132 Small molecule modulators of apoptosis
12/11/2003US20030229112 Synergistic mixture of temozolomide and irinotecan
12/11/2003US20030229109 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same
12/11/2003US20030229108 Angiogenesis inhibitors; antitumor agents, anticancer agents
12/11/2003US20030229098 Polycyclic compounds exhibiting anti-tumor activities
12/11/2003US20030229093 Lipid diseases; metabolism diosrders; antiproliferative agents
12/11/2003US20030229088 Novel methods and compositions for alleviating pain
12/11/2003US20030229083 Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
12/11/2003US20030229072 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binning agents
12/11/2003US20030229068 Controlling apoptosis, cell proliferation; strokes; anticancer agents; central nervous system disorders
12/11/2003US20030229067 Sedative, vasodilation, antiarrhythmia agents, antiallergens, antiinflammatory agents
12/11/2003US20030229064 Method of treating cancer using dithiocarbamate derivatives
12/11/2003US20030229051 Anticancer agents; restenosis; atherosclerosis; skin disorders
12/11/2003US20030229047 Liquid formulation of decitabine and use of the same
12/11/2003US20030229023 Anticancer agents; skin disorders; antiinflamamtory agents; antiarthritic agents
12/11/2003US20030229020 Vaccine; induce immunology response; administering monoclonal antibodies
12/11/2003US20030229008 Regenerating organs; anticancer agents; autoimmune disease; stabilization cells
12/11/2003US20030228663 Polypeptides comprising light and variable chains domains for use in the treament of cancer
12/11/2003US20030228640 Using early prostate antigen as tool in diagnosis, prognosis and treatment of cancer
12/11/2003US20030228634 Expression vectors encoding epitopes of target-associated antigens and methods for their design
12/11/2003US20030228606 Her-2 receptor tyrosine kinase molecules and uses thereof
12/11/2003US20030228576 Nucleotide sequence coding for a cleaving enzyme; can use in conjuction with substrate to produce toxins which impair abnormal cell growth; antitumor agents
12/11/2003US20030228568 Inducible phosphofructokinase and the warburg effect
12/11/2003US20030228365 Pharmaceutical formulation
12/11/2003US20030228355 Precipitation of lipid; fineness particle size
12/11/2003US20030228318 PSCA: prostate stem cell antigen and uses thereof
12/11/2003US20030228305 Compositions and methods for the diagnosis and treatment of tumor
12/11/2003US20030228281 Use of mutant herpes viruses and anticancer agents in the treatment of cancer
12/11/2003US20030228273 Novel high viscosity embolizing compositions comprising prepolymers
12/11/2003US20030228262 Diagnosis, therapy, image of celluloar disorders; antitumor agents
12/11/2003US20030228257 Induction apoptosis; antiarthritic agents
12/11/2003CA2736974A1 Tumour-associated peptides that bind to mhc molecules
12/11/2003CA2736972A1 Tumour-associated peptides that bind to mhc molecules
12/11/2003CA2736926A1 Tumour associated peptides that bind to mhc molecules
12/11/2003CA2736921A1 Tumour-associated peptides that bind to mhc molecules
12/11/2003CA2706635A1 Camptothecins with a modified lactone ring
12/11/2003CA2494451A1 Treatment of cell proliferative disorders with chlorotoxin
12/11/2003CA2491420A1 Rb1 gene induced protein (rb1cc1) and gene
12/11/2003CA2488287A1 Use of a synergistic combination of chlorogenic acid and 3-o-p-coumaryl quinic acid as an anti-leukemic therapy
12/11/2003CA2488251A1 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same
12/11/2003CA2488048A1 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
12/11/2003CA2488013A1 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
12/11/2003CA2487939A1 Semaphorin-like proteins and methods of using same
12/11/2003CA2487905A1 Use of cgmp - stimulating compounds
12/11/2003CA2487757A1 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
12/11/2003CA2487720A1 Therapeutic agent-containing polymeric nanoarticles
12/11/2003CA2487692A1 Methods and compositions for radioimmunotherapy of brain and cns tumors
12/11/2003CA2487679A1 Inhibitors of jak and cdk2 protein kinases
12/11/2003CA2487678A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
12/11/2003CA2487425A1 Combination chemotherapy with chlorotoxin
12/11/2003CA2487293A1 Use of new etonogestrel esters
12/11/2003CA2487291A1 Human prolactin antagonist-angiogenesis inhibitor fusion proteins
12/11/2003CA2487171A1 Method for the protection of endothelial and epithelial cells during chemotherapy
12/11/2003CA2486530A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
12/11/2003CA2486174A1 Xanthine phosphodiesterase v inhibitor polymorphs
12/11/2003CA2484515A1 Solid hydrogel coupling for ultrasound imaging and therapy
12/11/2003CA2484451A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/11/2003CA2482639A1 3-substituted quinuclidines and their use
12/11/2003CA2454654A1 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
12/11/2003CA2431806A1 Compositions for cancer therapy
12/10/2003EP1369487A2 Recombinant vectors derived from adenovirus for use in gene therapy
12/10/2003EP1369482A1 Target genes for the diagnosis and treatment of cancer
12/10/2003EP1369421A1 Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives
12/10/2003EP1369419A1 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
12/10/2003EP1369418A1 Quinazoline derivatives
12/10/2003EP1369132A1 Oxaliplatin containing liposome preparation
12/10/2003EP1369126A1 Use of coding microsatellite region frameshift mutation-derived peptides for treating cancer
12/10/2003EP1369122A1 Anticancer agent
12/10/2003EP1369117A1 Use of derivatives and precursors of oxaziridine in the treatment of cancerous tumours
12/10/2003EP1369116A1 Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
12/10/2003EP1369115A1 Methods of preventing breast cancer by the administration of Raloxifene
12/10/2003EP1368660A2 Assay
12/10/2003EP1368502A2 Alkynylated single-strand oligonucleotide and uses thereof
12/10/2003EP1368474A1 Polynucleotide useful for modulating cancer cell proliferation
12/10/2003EP1368470A2 Transcriptional mediators of blood vessel development and endothelial differentiation
12/10/2003EP1368459A2 Influenza viruses with enhanced transcriptional and replicational capacities
12/10/2003EP1368458A2 Interferon-alpha induced gene
12/10/2003EP1368457A1 Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells
12/10/2003EP1368378A2 Constitutively desensitized g protein-coupled receptors
12/10/2003EP1368371A2 Transfection complexes
12/10/2003EP1368365A2 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
12/10/2003EP1368357A1 Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds
12/10/2003EP1368355A2 Substituted pyrazolopyrimidines and thiazolopyrimidines
12/10/2003EP1368341A1 Phenyl derivatives 3
12/10/2003EP1368328A1 Methods for preparing new taxoids and pharmaceutical compositions containing them
12/10/2003EP1368327A1 Benzo thiadiazine matrix metalloproteinase inhibitors
12/10/2003EP1368324A1 Quinazolines as mmp-13 inhibitors
12/10/2003EP1368323A1 Pyrimidine matrix metalloproteinase inhibitors
12/10/2003EP1368320A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof
12/10/2003EP1368319A1 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands
12/10/2003EP1368318A2 Calcilytic compounds
12/10/2003EP1368317A1 Tryptase inhibitors
12/10/2003EP1368312A1 Benzo'f!isoindole derivatives with affinity to the ep4 receptor
1 ... 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 ... 2211